Member Info for Harrogate4

This is like the Yes No Interlude on Take your Pick. Google it.

Non technical analysis ----about half way down give or take.

Roche,Glaxo, Novartis could all be partners, but let's hope that tomorrow brings us LTHs some good news that moves the SP up to more realistic levels.

Anyone else having problems today?

That's been the way with Avacta all the way as far as I can see , so the sooner it lists in the US and gets some mainstream publicity the better.

BuenaVista---Agree 100% and the sooner the better. HMG not up to the job.

Anyone heard anything from any of them recently? Are they still with us? Are they still getting on with it?

Do let us know --anything will do!

And what does your source say?

Has been taken over by US based healthcare outfit ICR Westwicke offering improved opportunities in the US to its clients.

Indicative of Avacta listing in US?

BuenaVista --Thanks

Noted that David Browning is the Board Chairman!

But what does the OBN actually stand for -- had a brief look on Google but can't find it.

In the balance between "Avacta are just getting on with it" and "The new spirit of improved Comms" we need some input/update from AS.

The last comm (of significance) was in June-completion of 5th dose escalation in AVA6k.

Note that Consilium Strategic Communications ( appointed by Avacta on 5th July) still have not updated their website to confirm they have been appointed. They need to start communicating as to what they are doing.

Silence may be golden but is no friend to the SP.

Unless, of course, they have nothing to say.

Caught part of news item near end of ITV News at about 7.15pm this evening about fantastic results of a cancer treatment for blood cancer in one of their trials. Was it us?

Struggled intellectually with Dr Tap's tour de force but, in addition to any mention of AVA6000, another elephant not in the room was Medical Ethics. I suspect that Dr Tap, who has crossed the Atlantic to be with Avacta on their Science Day in February and has also chosen to run the extensive ongoing Phase 1a AVA6000 trials at various MSK branches in the US, does not usually associate himself with failure. I think he is certain of AVA 6000 success given current progress, and that the main purpose of his lecture was to lay out the current situation regarding Sarcomas and their treatments/failures/successes/trial designs/lessons learned etc and to invite the great and the good present to consider alternative ways forward, such that patients would receive life saving benefits sooner rather than later.

He probably envisages the imminent approach of situations where medical ethics require the imposition of new treatments rather that continuing with existing standards of care.

Just my thoughts.

Vertizea-Sun --Thanks for your res ipsa loquitur explanation to my quo vadis enquiry about Consilium and hope you are correct.

I think its the lack of professional standards that amazes me most about Consilium in that surely you would update your website after being engaged by Avacta for nearly a month.

Or are these expectations unrealistic nowadays.

Why have Avacta engaged Consilium Strategic Communications --appointed with immediate effect on 5th July. There has now been time for a few introductions & some biscuits to quote gje 306 from 21st July at 15.23, but the combination of the increasingly low SP, Avacta's unwillingness to attempt to boost the SP and Consiliums's seemingly complete inaction to date is, to be charitable, complex.

Consilium haven't even updated their website to confirm they have been appointed by Avacta (Consilium News).

Any ideas as to what the game plan is here because I haven't got a clue?

Since the announcement ( by tweet) on 5th July that Consilium had been appointed as Avacta's investor and media relations advisor with immediate effect, has anybody noted if they have done anything to improve the low level of the SP?

I may have missed it.

2p? ---you presumably mean 0.2p.

Drug firms' plea: Rejoin Horizon

Front page of today's Times Business Section (on page27 ).

This was in the Mail on Sunday today and written by Moira Petty. A good article dealing with the distress caused by the hair loss following chemotherapy.

Wouldn't it be great if they also did a follow up about chemo treatments that could avoid or minimise hair loss. No doubt Consilium the new Avacta Nomad/Broker are already on to it.